Clinical Trial
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma
- PMID: 413624
Item in Clipboard
Clinical Trial
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma
Cancer Treat Rep.
1977 Dec.
Abstract
The combination of two nonalkylating agents, hexamethylmelamine (HMM) and 5-fluorouracil (5-FU), was evaluated in 14 patients with advanced ovarian carcinoma. Nine patients had been treated previously with alkylating agents. The overall response rate was 36% which is not greater than could be expected with either HMM or 5-FU alone. However, the median survival of the five responders was greater than 24 months. Treatment had to be discontinued in five of 14 patients due to excessive toxicity. Although the toxic effects were predominately gastrointestinal, unpredictable hematopoietic and neurotoxic effects were observed.
Similar articles
-
Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.Natl Cancer Inst Monogr. 1975 Oct;42:169-72. Natl Cancer Inst Monogr. 1975. PMID: 825778 Clinical Trial.
-
Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2053-6. Cancer Treat Rep. 1979. PMID: 118805 Clinical Trial.
-
Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.Cancer Treat Rep. 1979 Jan;63(1):137-8. Cancer Treat Rep. 1979. PMID: 105805 Clinical Trial. No abstract available.
-
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?Cancer Treat Rep. 1986 Aug;70(8):1003-14. Cancer Treat Rep. 1986. PMID: 3089597 Review.
-
The role of hexamethylmelamine in advanced ovarian carcinoma treatment.Gynecol Oncol. 1981 Oct;12(2 Pt 1):141-9. doi: 10.1016/0090-8258(81)90143-8. Gynecol Oncol. 1981. PMID: 6795094 Review. No abstract available.